Immunohistochemical evaluation of the probability of skin metastasis in gastric cancer

European Journal of Dermatology

Volumn 9, Issue 3, 1999, Pages 214-217

  Inadomi, Toru ^a   Tan, Miyuki ^a   Suzuki, Hiroyuki ^a   Shigematsu, Chihiro ^a  

^a NIHON UNIVERSITY   (Japan)

Author keywords

Cell cycle; Gastric cancer; Ki67; Metastasis; p53; PCNA

Indexed keywords

CYCLINE; KI 67 ANTIGEN; PROTEIN P53;

ADULT; ARTICLE; CASE REPORT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MITOSIS INDEX; PREDICTION; PROBABILITY; SKIN METASTASIS; STOMACH CANCER; SUBCUTANEOUS NODULE;

ADENOCARCINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; SKIN NEOPLASMS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032904212     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. 1. Weisman K, Graham RM. Systemic disease and the skin. In: Rook A, Wilkinson DS, Ebling FJG, Champion RH, ed. Textbook of Dermatology 5th edn. Vol. 2. Oxford: Blackwell Scientific Publications, 1992: 2412-6.
2. 2. Geary WA, Cooper PH. Proliferating cell nuclear antigen (PCNA) in common epidermal lesions. J Cutan Pathol 1992; 19: 458-68.
3. 3. Tsuji T, Shrestha P, Yamada K, Takagi H, Shinozaki F, Sasaki K, Maeda K, Mori M. Proliferating cell nuclear antigen in malignant and pre-malignant lesions of epithelial origin in the oral cavity and the skin: an immunohistochemical study. Virchows Archiv A Pathol Anat 1992; 430: 377-83.
4. 4. Healy E, Angus B, Lawrence CM, Rees JL. Prognostic value of Ki67 antigen expression in basal cell carcinomas. Br J Dermatol 1995; 133: 737-41.
5. 5. Onodera H, Nakamura S, Sugai T. Cell proliferation and p53 protein expression in cutaneous epithelial neoplasms. Am J Dermatopath 1996; 18: 580-8.
6. 6. Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, Funke I, Izbicki JR, Riethmuller G. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993; 85: 1419-24.
7. 7. Maeda K, Chung YS, Takatsuka S, Ogawa Y, Sawada T, Yamashita Y, Onoda N, Kato Y, Nitta A, Arimoto Y, Kondo Y, Sowa M. Tumor angiogenesis as a predictor of recurrence in gastric carcinoma. J Clin Oncol 1995; 13: 477-81.
8. 8. Makino H, Naito K, Tsuruta A, Kan K, Toda S, Yoshimura N, Ohmori Y, Oka T. A case of complete remission of metastatic skin carcinoma (erythema type) from advanced gastric cancer by CDDP administration. Japan J Cancer & Chemotherapy 1993; 20: 2225-8.
9. 9. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71: 587-91.
10. 10. Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, Wanders J, Franklin H, LeBail N, Verweij J. Docetaxel (Taxotere™) in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer 1994; 70: 380-3.
11. 11. Tokunaga A, Onda M, Okuda T, Teramoto T, Fujita I, Mizutani T, Kiyama T, Yoshiyuki T, Nishi K, Matsukura N. Clinical significance of epidermal growth factor (EGF), EGF receptor and c-erbB-2 in human gastric cancer. Cancer 1995; 75: 1418-25.
12. 12. Kirkegaard LJ, DeRose PB, Yao B, Cohen C. Image cytometric measurement of nuclear proliferation markers (MIB-1, PCNA) in astrocytomas. Prognostic significance. Am J Clin Pathol 1998; 109: 69-74.
13. 13. Girod SC, Groth W, Junk M, Gerlach KL. p53 and PCNA expression in malignant melanomas of the head and neck. Pigment Cell Res 1994; 7: 354-7.
14. 14. Einspahr J, Alberts DS, Aickin M, Welch K, Bozzo P, Levine N, Grogan T. Evaluation of proliferating cell nuclear antigen as a surrogate end point bio-marker in actinic keratosis and adjacent, normal-appearing, and non-sun-exposed human skin samples. Cancer Epidemiol Biomarkers & Prevention 1996; 5: 343-8.
15. 15. Yonemura Y, Kimura H, Fushida S, Tugawa K, Nakai Y, Kaji M, Fonseca L, Yamaguchi A, Miyazaki I. Analysis of proliferative activity using antiproliferating cell nuclear antigen antibody in gastric cancer tissue specimens obtained by endoscopic biopsy. Cancer 1993; 71: 2448-53.
16. 16. Brooks DJ, Garewal HS. Measures of tumor proliferative activity. Int J Clin Lab Res 1992; 22: 196-200.
17. 17. Gartel AL, Serfas MS, Tyner AL. p21-Negative regulator of the cell cycle. Proc Soc Exp Biol Med 1996; 213: 138-49.
18. 18. Liu M, Pelling JC. UV-B/A irradiation of mouse keratinocytes results in p53-mediated WAF1/CIP1 expression. Oncogene 1995; 10: 1955-60.
19. cip1 in muscle and other terminally differentiating cells. Science 1995; 267: 1024-7.
20. 20. Ma CK, De Peralta MN, Amin MB, Linden MD, Dekovich AA, Kubus JJ, Zarbo RJ. Small intestinal stromal tumors: a clinicopathologic study of 20 cases with immunohistochemical assessment of cell differentiation and the prognostic role of proliferation antigens. Am J Clin Pathol 1997; 108: 641-51.
21. 21. Nylander K, Schildt EB, Eriksson M, Roos G. PCNA, Ki-67, p53 bcl-2 and prognosis in intraoral squamous cell carcinoma of the head and neck. Anal Cell Pathol 1997; 14: 101-10.
22. 22. Harris CC. p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and cancer risk assessment. Environ Health Perspect 1996; 104 (suppl. 3): 435-9.